Mei Ri Jing Ji Xin Wen·2025-08-14 14:03Core Viewpoint - JD Health reported strong financial performance for the first half of 2025, with significant growth in revenue and profit driven by the sales of pharmaceutical and health products [1] Financial Performance - The company achieved revenue of 35.29 billion yuan, representing a year-on-year growth of 24.5% [1] - Operating profit reached 2.13 billion yuan, marking a substantial increase of 105.5% year-on-year [1] - Net profit attributable to shareholders was 2.60 billion yuan, reflecting a year-on-year growth of 27.45% [1] Business Segments - JD Health's revenue growth was primarily fueled by the sales of pharmaceutical and health products, which increased by 22.7% to 29.3 billion yuan compared to the same period last year [1] - The company launched over 30 innovative drugs online in the first half of the year, including weight loss drug Xin'ermei and hypertension treatment drug Xinchao Tuo [1] User Engagement and Platform Growth - As of June 30, 2025, the number of merchants on JD Health's platform exceeded 150,000, an increase of over 50,000 since December 31, 2024 [1] - The annual active user count surpassed 200 million, with an average of over 500,000 consultations per day in the first half of the year [1]